With the purpose of study of clinical efficiency and safety of new preparation Altan, which had been synthesized with Ukrainian pharmaceutical academy, 44 patients with chronic hepatic diseases were examined. The action of altan was studied in 21 patient including 12 patients with chronic persistent (CPH) and 9 patients with chronic reactive hepatitis (CRH) on the background of inflammatory diseases of gallbladder and biliary tracts. The preparation was prescribed in dose 0.01 g (1 tablet) 3 times a day 1 hr before meals on the background of complex therapy using vitamins. The control group was composed of 22 patients, including 10 patients with CPH) and 12 patients with CRH, who were treated with silibor (S) in dose 0.04 g (1 tablet) 3 times a day before meals in combination with vitamins. On therapy commencement the abdominal and pain syndrome occurred in 81% of patients in the basic group. At the end of 2nd week of treatment a moderate dull pain in epigastrium right half remained only in 6 patients (29%), who were treated with altan. The action of silibor on the dynamics of pain syndrome cupping was less expressed as compared with the basic group (68% and 32% correspondingly. The dynamics of asthenic syndrome cupping in both basic and control groups was not reliably differed. At the end of treatment in 15 patients of the basic group bitter in mouth, nausea, eructation completely disappeared and only in 6 patients (29%) meteorism and bitter in mouth retained in the morning. In the control group dyspeptic complaints remained in 32% cases. No reliable differences in the rate of liver size reduction in patients of the two groups under comparison were ascertained. The biochemical blood count had shown no essential intergroup differences in dynamics of indicators characterizing pigment-forming and protein-synthesis functions of the liver. Reduction or complete normalization of levels of cytolytic ferments and gamma-globulins in blood serum in patients of both basic and control groups was noted, which fact demonstrated comparable anti-inflammatory activities of altan and silibor in patients with chronic hepatic diseases. In patients of the basic group spontaneous chemiluminescence intensity was very high (23.01 + 2.04 p.p.s), after treatment it reduced by 75.1% (5.73 + 0.69 p.p.s). In control group it reduced by only 36.1% (22.13 + 2.7 p.p. and 14.14 + 1.04 p.p.s correspondingly), which fact demonstrates an expressed antiradical action of altan. Malonic dialdehyde content in blood with and without initiation nicotine amide adenine dinucleotide phosphate Н2, ascorbate and Fe2+, which was very high before treatment, reliably reduced in patients of the basic group: with CPH by 25% to 35.7% and with CRH by 34.9 to 44.9%. In patients of the control group only the value of uninitiated malonic dialdehyde somewhat reduces by 18.9 to 21.5%. Thus, altan is effective in therapy of chronic hepatic diseases, positively affects the progress of lipids peroxidation process, mainly due to better antioxidant protection of hepatocyte membrane, facilitates normalization of bioenergetic processes therein and accelerates reduction of inflammatory process activity in liver tissues. By its anti-inflammatory and hepato-protecting activity this preparation does not yield preparation silibore, which fact makes it possible to recommend Altan for a wide application in treatment of patients with chronic liver diseases.